Today’s Q3 results are in line with our expectations. Good progress is being made developing ensifentrine for use in COPD, with data from the final, fully enrolled, 4-week Phase IIb dose-ranging study expected around YE 2019. We look forward to results from this trial, which we see as key to capturing the full commercial potential of ensifentrine. The trial is expected to conclude the comprehensive Phase II programme, with an FDA End of Phase II Meeting anticipated in H1 2020. Verona is expected ....
05 Nov 2019
In line Q3 update with final Phase IIb data expected around YE 2019
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
In line Q3 update with final Phase IIb data expected around YE 2019
Verona Pharma plc Sponsored ADR (VRNA:NAS) | 0 0 0.0%
- Published:
05 Nov 2019 -
Author:
Edward Thomason -
Pages:
3
Today’s Q3 results are in line with our expectations. Good progress is being made developing ensifentrine for use in COPD, with data from the final, fully enrolled, 4-week Phase IIb dose-ranging study expected around YE 2019. We look forward to results from this trial, which we see as key to capturing the full commercial potential of ensifentrine. The trial is expected to conclude the comprehensive Phase II programme, with an FDA End of Phase II Meeting anticipated in H1 2020. Verona is expected ....